News

BIO Announces Appointment of Interim CEO

Established Industry Leader Rachel King will Serve as BIO’s Interim Leader

WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) – the world’s largest science and public advocacy organization, representing 1,000 members — announced today that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO. King’s appointment follows Dr. Michelle McMurry-Heath stepping down as President and CEO to serve as an Advisor to the Executive Committee of the BIO Board of Directors. The organization is searching for a full-time successor.

A long-standing member of the BIO leadership, King brings deep expertise across the industry and previously served as Chair of the BIO Board. King has experience at small and large companies having served as co-founder and former CEO of GlycoMimetics, Inc. and as a senior vice president of Novartis Corporation. Prior to that role she spent more than a decade at Genetic Therapy Inc., including as the company’s CEO. She also served at ALZA Corporation and at Bain & Company. She is an expert in the innovation ecosystem as a former Entrepreneur in Residence at New Enterprise Associates, one of the nation’s leading venture capital firms.

“I am deeply committed to the mission and vision of BIO. I look forward to working with BIO’s talented staff and its members,” said Rachel King, Interim President & CEO. “Together, we are going to continue to tackle important policy issues related to health, agriculture, and the environment. Our work advances science and technology and touches people of all backgrounds to improve human health and well-being. The strategy of BIO remains on track.”

“We are delighted that Rachel King has agreed to take on this interim CEO role as we search for a successor. She is a highly experienced biotech executive who has served in large pharmaceutical organizations as well as an entrepreneur who co-founded her own biotech company. We look forward to working together with Rachel and the staff at BIO to continue important efforts that support innovation for people and patients in all aspects of biotechnology from food and agriculture to healthcare,” said Paul Hastings, Chair BIO Executive Committee & Board of Directors.

King will be working closely with the BIO staff to advance innovation that benefits people and patients across BIO’s key initiative areas: food and agriculture, industrial and environment, health biotechnology and emerging biotechnology companies.

Read more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …